

RSC Advances

Linearization of carbohydrate derived polycyclic frameworks

Journal:	RSC Advances
Manuscript ID:	RA-ART-05-2014-004845.R1
Article Type:	Paper
Date Submitted by the Author:	29-Jun-2014
Complete List of Authors:	Panda, Gautam; Central Drug Research Institute, Medicinal and Process Chemistry Singh, Priyanka; Central Drug Research Institute, Medicinal and Process Chemistry

SCHOLARONE[™] Manuscripts Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxx



Linearization of carbohydrate derived polycyclic frameworks

Priyanka Singh,^a Gautam Panda^{*a}

Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram 5 Extension. Sitapur Road. Lucknow 226031. UP. India Tel: 91-522-2612411-18, Ext. 4661, 4662; Fax: 91-522-2623405

E-mail: gautam.panda@gmail.com; gautam panda@cdri.res.in

Received (in XXX, XXX) Xth XXXXXXXX 20XX, Accepted Xth XXXXXXXX 20XX DOI: 10.1039/b000000x

10 We report an easy access to carbohydrate derived diverse tricyclic skeletons which could be beneficial for exploring polyfunctionalized chiral alicycles. The key reaction to assemble sugar fused tricyclic core is intermolecular tandem esterification and 1,3-dipolar cycloaddition. The framework was elaborated using amide forming reactions, opening of isoxazolidine rings followed by N and Oacylations. The sequences provide distinct, spatially separated and encoded chemical entities that may pave the way to investigate cell functions.

Introduction:

15

The powerful effects of structurally complex small molecules having stereochemical and skeletal diversity and functionalities have been manifested to exhibit highly specific biological

- 20 responses. In this area, complexity of small molecules is essential since many biological processes are significantly dependent upon protein-protein interactions, and most of the small molecules known to interrupt these interactions are structurally complex natural products and natural product like 25 molecules (Figure 1). The natural products; Taxol and
- Discodermolide bind and activate, the protein tubulin,¹ which itself was discovered as the protein target of colchicines.^{2,3,4}



Figure 1

- 30 Diversity is also important since in these screens, there is no particular target and whereas an eventual target could be any one of the cells or organisms entire collection of macromolecules in phenotypic screening of small molecules. In this context, new methodologies have to be designed for stereoselective synthesis
- 35 of small molecule with distinct skeletal frameworks having structural features reminiscent of natural products.

complex small molecules, we employed carbohydrates as chiral pool that would provide an access to a large array of molecules ⁴⁰ since it display a high density of functional groups, are available as single enantiomers and contain multiple sites for attachment of recognition groups. Decrease in the conformational freedom of small molecules

Following our interest in the field of synthesis of structurally

can facilitate protein binding and specificity by dropping the 45 entropic cost of binding. In natural products, macrocyclic, polycyclic, or highly substituted linear structures result restriction in conformational freedom (Figure 1). Proper combination of hydrogen bonding and hydrophobic functional groups offer the enthalpic driving force for protein binding. 50 Herein, we report a strategy for highly efficient access to similarly constructed molecules from carbohydrate derived tricyclic rigid framework. We have also described our efforts towards generation of an acyclic series of highly functionalized compounds with defined chirality after disintegrating sugar 55 based skeleton.

Result and discussion:

Initially, we focused our attention to synthesize tricyclic compounds by coupling of glucal derived allylic alcohol 4⁶ with nitrone ester 5 by using a reaction catalyzed by lewis acid ⁶⁰ followed by intramolecular 1,3-dipolar cycloaddition.⁵ Synthesis of 4 was commenced from commercially available tri-O-acetylglucal 1. Treatment of 1 with dry methanol in presence of catalytic amount of iodine furnished 2^6 via ferrier rearrangement.⁷ Deacetylation of **2** using K₂CO₃ in methanol $_{65}$ furnished diol 3^8 which on selective protection of primary alcohol as TBDMS ether yielded allylic alcohol 4 (scheme 1).



Reagents and condition: (a) Methanol, I_2 , THF, 1.5h, 85% (b) K_2CO_3 , MeOH, 30 min; 90% (c) TBDMS-Cl, imidazole, dry 5 DCM, 30 min, 95%.

Scheme 1

1,3-dipolar cycloaddition^{9,10} was attempted between nitrone ester **5** and allyl alcohol **4**. Unfortunately, instead of tricyclic product **6**, complex mixture of products was observed ¹⁰ (Scheme 2). This might be due to the presence of acid labile TBDMS group.



Reagents and conditions: (a) TiCl₄, 4A°MS, DCE, rt, overnight. Scheme 2

- ¹⁵ However, it has been reported that reaction of lewis acid on a molecule having template similar to **4** gave rearranged product 2-substituted furan.¹¹ Since Lewis acid catalyzed reaction was not successful with our substrates, we decided to follow Schreiber's methodology¹² in order to get tricyclic framework.
- ²⁰ Towards this goal, nitrone carboxylic acid **11** was synthesized.¹³ Synthesis of **11** was started with oxime **9** which was synthesized through condensation of 4-methoxy benzaldehyde **7** with hydroxylamine hydrochloride **8**. Reduction of **9** using NaBH₃CN under acidic condition gave *N*-alkyl hydroxyl amine **10**.¹⁴
- ²⁵ Condensation of *N*-alkyl hydroxyl amine **10** with glyoxylic acid mono hydrate furnished **11** (scheme 3).



Reagent and conditions: (a) 10% KOH:H₂O, 0⁰C, 2h, 74% (b) NaBH₃CN, MeOH, 2N HCl, 3h, 72% (c) CHO-COOH, DCM, ³⁰ overnight, 75%.

Scheme 3

Unfortunately 1,3 dipolar cycloaddition of **4** with nitrone corboxylic acid **11** did not yield any tricyclic product (scheme 4).



Reagents and conditions: (a) PyBroP, DIPEA, DMAP, DCM, 0°C-rt, overnight.

Scheme 4

Disappointing with these results, we decided to design some new ⁴⁰ sugar derived allylic alcohol. In this context, galactose derived allylic alcohol **18** was undertaken.



Reagents and conditions: (a) DMP, CSA, acetone, 12h, 60% (b) Ac₂O, pyridine, 12h, 91% (c) 80% AcOH:H₂O, 80 °C, 2 h, 45 94% (d) PPh₃ CHI₃, imidazole, toluene, reflux, 2.5 h, 94% (e) NaOMe, MeOH, 30min, 95% (f) TBDMSCl, imidazole, DCM, 30 min, 95%.

Scheme 5

Synthesis of **18** was started with commercially available ⁵⁰ methyl α-methyl-D-galactopyranoside **12** as shown in scheme **4**. Compound **13** was obtained by acetonation of **12** with 2,2dimethoxypropane (DMP) and catalytic amount of camphor sulfonic acid (CSA) in acetone. Acetylation of diol **13**¹⁵ provided protected **14**¹⁶ which on acidic hydrolysis with 80% AcOH ⁵⁵ furnished diol **15**.¹⁷ Removal of vicinal diol by treatment with PPh₃, CHI₃, imidazole in toluene under refluxing condition provided olefin **16**¹⁸, which on subsequent deacetylation and TBDMS protection of primary alcohol **17**¹⁹ furnished allylic alcohol **18**²⁰ (scheme 5).

⁶⁰ Treatment of the allylic alcohol **18**, with **11**, under esterification conditions yielded tricyclic compound **19** with complete regio- and stereoselectivity, presumably *via* tandem acylation and 1,3-dipolar cycloaddition.⁹ No intermediate nitrone ester or carboxy isoxazolidine structures was observed (Scheme ⁶⁵ 6).



Reagents and conditions: (a) PyBroP, DIPEA, DMAP, DCM, 0°C-rt, overnight, 95%.

Scheme 6

The stereochemistry of **19** was confirmed on the basis of 1H and 2D NMR spectrum. The appearance of two doublet of doublet at 4.62 δ (*J* = 4.4, 3.2) and 4.17, and two doublet at 5.03 δ (*J* = 2.9) and 4.36 δ (*J* = 5.8) in 1H NMR data of **19** clearly indicated the ⁵ cis relationship between H1, H2, H3, H3' and H4. The small coupling constant confirmed the stereochemistry of **19**. In addition to this, significant NOESY correlations are shown in Figure 2 whereas H-3' showed the NOESY correlation to H-3 and H-2. H-3 showed NOESY correlation to H3', H-4 and H-2.



- With tricyclic framework in hand, we tried to access a series of ¹⁵ linear molecule having structural features reminiscent of natural products from tandem ring opening on carbohydrate derived rigid tricyclic skeleton **19**. The nucleophile can react with electrophilic lactone of **19** while simultaneously unmasking alcohols for successive reactions. Furthermore, reductive N-O
- ²⁰ bond cleavage would offer two additional appendages for functionalization. In this endeavor, we first selected to open the sugar ring. The reaction sequence involved was opening of silyl group by tetrabutyl ammonium fluoride (TBAF) in dry THF. Unfortunately, we did not get any deprotected product but ²⁵ complex mixture of products was observed. However, treatment
- of **19** by 1(N) aq. HCl in THF furnished alcohol **20**. Next plan was to convert alcohol **20** into iodo compound **21**.



Reagents and conditions: (a) TBAF, dry THF, 30 min.; (b) ³⁰ PPh₃, I₂, imidazole, dry toluene, reflux, 3h; (c) 1N aq. HCl, THF, 30 min, 95% (d) LAH, dry THF, 0°C, 1h, 95% (e) LAH, dry

THF, reflux, 3 days; (f) DIBAL-H, amine, dry THF, 0 °C to rt, 2.5h, 85%.

Scheme 7

Treatment of 20 with PPh₃, I₂ and imidazole in dry toluene 35 under refluxing condition provided iodo compound 21 (Scheme 7).²¹ Purification of **21** was problematic due to the much similar R_f value of side product triphenyl phosphine oxide and 21. So we decided first to open the lactone ring of 19 before opening of 40 sugar ring, thinking that it may change the polarity of products making purification of iodo compound easier. Reduction of lactone of 19 with reducing agents like NaBH₄ and LAH gave hemiacetal 22. However, reaction of 19 with LAH under refluxing condition for 3 days gave diol 23 in trace amount 45 leaving the unreacted hemiacetal 22. The reason for the inertia to reduction may presumably be due to an initial formation of a highly stable complex.²² Failure of reduction of lactone of 19 prompted us to investigate other reactions on it. Gratifyingly, aminolysis of 19 with DIBALH-NH2R complex in dry THF ⁵⁰ furnished amide **24**.²³ Protection of secondary alcohol did not work under standard condition like benzylation, acetylation and coupling reactions. So we thought to proceed further with 24. Towards our aim of opening the sugar ring, treatment of 24 with 1(N) aq. HCl for deprotection of silvl ether unfortunately 55 furnished the recovery of compound 20 (Scheme 7). Above mentioned unsuccessful attempts to get diverse acyclic molecules from tricyclic 19 prompted us to synthesize a new tricyclic compound containing iodo functionality. Thus, we synthesized an allylic alcohol 29.



Reagent and conditions: (a) I_2 , PPh₃, Imidazole, toluene, 60° C, 2.5 h, 75% (b) Ac₂O, pyridine, 12h, 95% (c) 80%AcOH:H₂O, 65 80^oC, 1.5h, 85% (d) PPh₃, CHI₃, imidazole, toluene, reflux, 2.5h, 68% (e) K₂CO₃, MeOH, 30min, 78%.

Synthesis of **29** was commenced with **13** as shown in scheme **8**. Selective replacement of primary alcohol by iodo ⁷⁰ group using I₂, triphenylphosphine, imidazole in toluene at 60 °C furnished alcohol **25**.²⁴ Acetylation of **25** provided protected compound **26**²⁵ which on acidic hydrolysis with 80% AcOH furnished diol **27**. Removal of vicinal diol by treatment with PPh₃, CHI₃, imidazole in toluene under refluxing condition ⁷⁵ provided olefin **28**, which on subsequent deacetylation furnished allylic alcohol **29** (scheme 8). Treatment of **29** with nitrone carboxylic acid **18** under above mentioned esterification condition yielded tricyclic compound **21** (scheme 9). In this case also, intermediate nitrone ester or carboxy isoxazolidine ⁸⁰ structures were not observed.



Scheme 9

Reagent and conditions: (a) PyBroP, DIPEA, DMAP, DCM, 5 0°C-rt, overnight, 72%.

To synthesize highly functionalized diverse acyclic compounds, we initiated reactions to functionalize tricyclic **21**. In this endeavour, lactone ring was first undertaken. Aminolysis ¹⁰ of lactone of **21** under above mentioned condition furnished amides **30a-c**. This reaction proceeded very well with number of aliphatic, cyclic and aromatic amines as shown in scheme **10**.



Reagents and conditions: (a) DIBAL-H, Amine, Dry THF, 4h. Scheme 10

15

With compounds **30a-c** in hand, we aimed to open isoxazolidine ring. Treatment of **30** with Zn dust, NH_4Cl and THF at 65 °C furnished complex mixture of products. However, hydrogenolysis with $Pd(OH)_2$ under H_2 atmosphere gave

²⁰ hydrogenated product **31**. Gratifyingly, treatment with $Mo(CO)_6$ in acetonitrile and water mixture (15:1) under refluxing condition provided amino alcohol which was further protected by acetyl group to give **32**. (Scheme 11)



²⁵ Reagents and condition:(a) Pd(OH)₂, H₂, overnight;(b) Zn, NH₄Cl, THF, 65 °C, 1.5h; (c) (i) Mo(CO)₆, ACN:H₂O, reflux, 5h; (ii) Ac₂O, pyridine, overnight.

Scheme 11

The successful functionalization of lactone and isoxazolidine ³⁰ ring encouraged us to further derivatize the sugar ring. Treatment of tricyclic compound **21** with Mo(CO)₆ in acetonitrile and water mixture under refluxing condition gave amino alcohol **33**. On purification, amino alcohol **33** was not stable on column forcing us to proceed without purification. ³⁵ Treatment of **33** with acetic anhydride in pyridine yielded **34** which on treatment with zinc, ammonium chloride in THF and water mixture provided aldehyde **35**. Wittig olefination of crude aldehyde **35** with (carbethoxymethylene)triphenylphosphorane in dry CH₂Cl₂ at room temperature furnished α , β -unsaturated ⁴⁰ ester **36** (Scheme 12).



Reagents and condition:(a) $Mo(CO)_6$, $ACN:H_2O$, reflux (b) Ac_2O , pyridine, overnight, 72% over 2 steps (c) Zn, THF:H_2O, 45 65°C (d) Ph₃PCH₂COOEt, DCM, rt, overnight, 65%.

Scheme 12

The successful synthesis and functionalization of tricyclic compound 21 derived from α -D-galactopyranoside inspired us to initiate further application of this strategy for the synthesis of 50 another structurally related tricyclic derivatives using D-ribose derived homoallylic alcohol 42 and α -D-glucopyranoside derived allylic alcohol 52. The synthesis of 42 was achieved from D-ribose. Methylation of anomeric hydroxyl group of 37 using acetyl chloride in methanol followed by acetonation with 55 2,2-dimethoxypropane (DMP) and catalytic amount of camphor sulfonic acid (CSA) in acetone gave major isomer 38^{26} with trace amount of other isomer. Acetylation of 38 provided protected compound 39²⁷ which on acidic hydrolysis with 80% AcOH furnished diol 40.28 Removal of vicinal diol by treatment 60 with PPh₃, CHI₃, imidazole in toluene under refluxing condition provided olefin 41, which on subsequent deacetylation furnished homoallylic alcohol 42 (scheme 13).



Reagent and conditions: (a) (i) CH₃COCl, methanol, reflux, 12h, (ii) DMP, CSA, acetone, 12h, 78% (b) Ac₂O, pyridine, 12h, 95% (c) 80%AcOH:H₂O, 80⁰C, 1.5h, 81% (d) PPh₃, CHI₃, imidazole, toluene, reflux, 4h, 62% (e) NaOMe, MeOH, 30min, 578%.

Scheme 13

Synthesis of tricyclic compound **43** was achieved from coupling of homoallylic alcohol **42** with nitrone **12** by following the same reaction sequence as that described for **21** (scheme 14). ¹⁰ Stereochemistry of tricyclic **43** was confirmed by 2-D NMR spectrum.



Reagent and conditions: (a) PyBroP, DIPEA, DMAP, DCM, 15 0⁰C-rt, 62%.

Scheme 14

Next, we turned our attention to synthesize α,Dglucopyranoside derived alcohol **52**. Benzylidine protection of **44** using benzylidine dimethyl acetal and catalytic amount of ²⁰ camphor sulphonic acid (CSA) in acetone furnished diol **45**.²⁹ Protection of diol **45** as benzyl ether using BnBr, NaH in DMF yielded **46**.³⁰ Benzylidine deprotection of **46** using I₂ in methanol under refluxing condition for followed by TBDMS protection of primary alcohol **47**³¹ and mesyl protection of secondary alcohol ²⁵ **48**³² gave **49**.³³ Deprotection of TBDMS group of **49** using TBAF followed by swern oxidation of primary alcohol **50**³⁴ and subsequent reduction of aldehyde **51**³⁵ by sodium borohydride in methanol produced allylic alcohol **52**³⁶ in good yield (scheme 15).



Reagent and conditions: (a) Benzylidine dimethyl acetal, CSA, acetone, overnight; (b) BnBr, NaH, DMF; (c) I₂, methanol, reflux; (d) TBDMSCl, imidazole, DMF, 97% (e) MsCl, Et₃N, DCM, 0°C to rt, 80% (f) TBAF, THF, 30min, 95% (g) (COCl)₂, ³⁵ DMSO, DCM, DMAP, -78°C; (h) NaBH₄, methanol, 94%.

Scheme 15

Tricyclic compound 53 by using α -D-glucopyranoside derived allylic alcohol 52 was also easily synthesized following the same procedure as described for 21 but 53 was not ⁴⁰ diastereomerically pure but it was racemic (scheme 16).



Reagent and conditions: (a) PyBroP, DIPEA, DMAP, DCM, 0^{0} C-rt, 62%.

Scheme 16

45 Conclusion:

In summary, we have synthesized four carbohydrate derived tricyclic skeletons which could be useful for accessing polyfunctionalized chiral alicycles having structural features reminiscent of natural products. These tricyclic compounds were ⁵⁰ synthesized by using intermolecular coupling reaction followed by 1,3-dipolar cycloaddition among nitrone carboxylic acid and galactose, glucose derived allylic and ribose derived homoallylic alcohol. Among them, galactose derived tricyclic framework furnished densely functionalized molecules. These four step reaction sequences resulted in a collection of compounds containing number of distinct, spatially separated, and encoded chemical entities that may pave the way for exploring chemical genetic approach. Efforts in this direction are currently underway.

60 EXPERIMENTAL SECTION

General

Organic solvents were dried by standard methods. All the products were characterized by ¹H, ¹³C, two-dimensional homonuclear COSY (correlation spectroscopy), heteronuclear 65 single quantum coherence (HSQC), Nuclear Overhauser effect spectroscopy (NOESY), IR, ESI-MS. Analytical TLC was performed using 2.5 x 5 cm plates coated with a 0.25 mm thickness of silica gel (60F-254) using UV light as visualizing agent and an acidic solution of ninhydrin, and heat as developing 70 agents. Column chromatography was performed using silica gel (60-120 and 100-200 mesh). NMR spectra were recorded on 300 MHz (¹H) and 50, 75 MHz (¹³C). Experiments were recorded in CDCl₃, (CD₃)₂CO and CD₃OD at 25 °C. Chemical shifts are given on the δ scale and are referenced to the TMS at 75 0.00 ppm for proton and 0.00 ppm for carbon. For ¹³C NMR reference CDCl₃ appeared at 77.00 ppm. IR spectra were recorded on FT-IR spectrophotometers. Optical rotations were determined by using a 1 dm cell at 28 °C in chloroform and methanol as the solvents; concentrations mentioned are in g/100 80 mL.

Experimental Procedures and Characterization Data

((2*R*,3*S*,6*S*)-3-acetoxy-6-methoxy-3,6-dihydro-2H-pyran-2yl)methyl acetate 2:

To a solution of **1** (5 g, 0.18 mol), methanol (1.5 mL) in THF (75 mL) was added iodine (0.90 g, 3.00 mmol). After being stirred on room temperature for 1.5 h under N_2 atmosphere, the mixture

was diluted with ether. The resulting dark red coloured mixture was washed with 50 mL of a 10% aq.Na₂S₂O₃ under stirring until the solution becomes colorless. The aqueous phase was extracted with ether. The combined organic layer was dried over

- ⁵ Na₂SO₄ and the solvent was evaporated under vacuo and residue was purified by column chromatography to give **2** (3.84 g, 85 %) as white gum. [α]_D²⁸= +140.1 (*c* 1.1, CHCl₃); eluent column chromatography: EtOAc/Hexane (5/45, v/v); R_f 0.30 (2/3 EtOAc/Hexane); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246,
- ¹⁰ 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 5.87-5.77 (m, 2H),
 5.29-5.25 (m, 1H), 4.88 (br s, 1H), 4.25- 4.12 (m, 2H), 4.05-3.99 (m, 1H), 3.43 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H). ¹³CNMR (75MHz, CDCl₃): δ 170.1, 169.7, 129.2, 127.7, 95.4, 66.9, 65.3,
 62.8, 55.7, 20.8, 20.6; MS (ESI): *m/z* 245 (M⁺+H). Anal. Calcd
 ¹⁵ for C₁₁H₁₆O₆: C, 54.09; H, 6.60. Found: C, 54.15; H, 6.65.

(2*R*,3*S*,6*S*)-2-((tert-butyldimethylsilyloxy)methyl)-6methoxy-3,6-dihydro-2H-pyran-3-ol 4:

To the stirred solution of 3 (0.90 g, 5.61 mmol) in dry DCM (15 mL), TBDMSCl (0.93 g, 6.18 mmol) and imidazole (0.57 g, 8.42 ²⁰ mmol) were added at 0 °C and allowed to stir for 30 min. After completion of reaction, it was diluted with water and extracted with dichlomethane (15 mL \times 3). The combined organic extracts were washed with brine, and dried over Na₂SO₄. The organic fraction was concentrated in vacuo to give 4 (1.46 g, 95%) as $_{25}$ colorless gum. $[\alpha]_{D}^{28}$ = + 69.2 (c 0.03, MeOH). R_f 0.80 (1/1 EtOAc/Hexane). Eluent for column chromatography: EtOAc/Hexane (7.5/22.5, v/v); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 5.93-5.87 (m, 1H), 5.72-5.64 (m, 1H), 4.79 (d, 1H, J = 1.3), 30 4.14- 4.06 (m, 1H), 3.93-3.81 (m, 2H), 3.79-3.59 (m, 1H), 3.40 (s, 3H), 2.82 (s, 1H), 0.92 (s, 9H), 0.11 (s, 6H). ¹³C NMR (75MHz, CDCl₃): δ 133.2, 125.7, 95.2, 70.6, 66.5, 65.1, 55.5, 25.9, 18.4, -5.36, -5.38; MS (ESI): m/z 275 (M⁺+H). Anal. Calcd for C₁₃H₂₆O₄Si: C, 56.90; H, 9.55. Found: C, 56.99; H, 9.63.

35 *N*-(2-ethoxy-2-oxoethylidene)-N-(4methoxybenzyl)hydroxylammonium 5:

To the solution of diethyl-d-tartrate (1.20 g, 6.00 mmol) in dry ether (20 mL) cooled in a cold water bath was added paraperiodic acid (1.33 g, 6.00 mmol) in portion over 1 h under ⁴⁰ nitrogen with stirring. The milky reaction mixture was then stirred for a few minutes until the ether solution had become almost clear and a white solid separated. The ether phase was decanted, dried with molecular sieves, evaporated, and distilled through a column to give clear ethyl glyoxylate (1.02 g, 82 %).

- ⁴⁵ To an ice cooled mixture of **10** (1.60 g, 11.00 mmol) and calcium chloride (0.29 g, 2.00 mmol) in 29 mL of ether, ethyl glyoxylate (1.02 g, 7.00 mmol) was added drop wise, after which the whole residue was stirred at 0 °C for 1 h. The solids were removed by filtration through an anhydrous Na₂SO₄, and the
- ⁵⁰ filtrate was evaporated to give **5** (1.64 g, 88%). Mp 84.0-86.5 °C; IR (KBr): 1720, 1560, 1200, 1045, 965, 825, 700 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 7.40 (m, 5H), 7.17 and 7.09 (s, 1H), 5.69 and 4.96 (s, 2H), 4.25 and 4.22 (q, 2H, J = 7.0), 1.30 and 1.27 (t,

3H, J = 7.0); MS (ESI): m/z 238 (M⁺+H). Anal. Calcd for ss C₁₂H₁₅NO₄: C, 60.75; H, 6.37; N, 5.90. Found: C, 60.82; H, 6.31; N, 5.96.

4-methoxybenzaldehyde oxime 9:

To the solution of hydroxyl amine hydrochloride **8** (7.65g, 0.11mol) in saturated solution of KOH, was added p-methoxy ⁶⁰ benzaldehyde **7** (10g, 0.07 mol) and allowed to stir for 2 hour at 0 °C. After completion of reaction, reaction mixture was filtered and residue was washed with cold water (200ml) and dried in air to give **9** (10.2g, 92%) as white solid. R_f 0.5 (1.5/3.5 EtOAc/Hexane); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, ⁶⁵ 1034 cm⁻¹. ¹H NMR (300 MHz, (CD₃)₂CO): δ 8.06 (s, 1H), 7.50 (t, 2H, *J* = 6.8), 6.95 (t, 2H, *J* = 1.9), 3.82 (s, 3H); MS (ESI): *m/z* 152 (M⁺+H). Anal. Calcd for C₈H₉NO₂: C, 63.56; H, 6.00; N, 9.27. Found: C, 63.62; H, 6.09; N, 9.34.

N-(4-methoxybenzyl)hydroxylamine 10:

70 To a solution of oxime 9 (1.78 g, 0.01 mol) and NaBH₃CN (1.11 g, 0.02 mmol) in 17 mL of methanol was added a trace of bromocresol green. A solution of 2 N HCl methanol was then added drop wise with stirring to maintain the yellow color. After ca. 15 min, the color changed very slowly. The solution was 75 stirred for 3 h, and the methanol was removed at reduced pressure. The residue was dissolved in 10 mL of water, raised to pH >9 with 6 N KOH, saturated with sodium chloride, and extracted with four 15-ml portions of chloroform. The combined extracts were dried over Na2SO4 and evaporated in vucuo to give 80 (1.35 g, 72%) of 10 as white solid. Rf 0.5 (1.5/3.5 EtOAc/Hexane); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, (CD₃)₂CO): δ 7.40 (d, 2H, J = 8.7), 6.91-6.88 (m, 2H), 4.97 (s, 2H), 3.79 (s, 3H); ¹³C NMR (75 MHz, (CD₃)₂CO): δ 160.1, 130.0, 127.7, 114.3, 63.4, 55.3; MS m_{z} (ESI): m/z 152 (M⁺+H). Anal. Calcd for C₈H₁₁NO₂: C, 62.73; H, 7.24; N, 9.14; Found: C, 62.82; H, 7.31; N, 9.21.

N-(carboxymethylene)-1-(4-methoxyphenyl)methanamine oxide 11:

To the solution of **10** (0.30 g, 1.95 mmol) in dry DCM (10 mL), ⁹⁰ glyoxalic acid (0.19 g, 2.05 mmol) was added and allowed to stir for overnight. After completion of reaction, it was diluted with water and extracted with dichloromethane (10 mL × 3). The combined organic extracts were washed with brine, and dried over Na₂SO₄. The organic fraction was concentrated in vacuo to ⁹⁵ give **11** (0.30 g, 75%) as white semi solid. R_f 0.2 (EtOAc); IR (Neat): 3450, 2926, 2366, 1718, 1253, 772 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 14.6 (brs, 1H), 7.33 (d, 2H, *J* = 8.6), 6.97 (d, 2H, *J* = 8.6), 4.99 (s, 2H), 3.84 (s, 3H); MS (ESI): *m/z* 210 (M⁺+H). Anal. Calcd for C₁₀H₁₁NO₄: C, 57.41; H, 5.30; N, 6.70. ¹⁰⁰ Found: C, 57.49; H, 5.40; N, 6.61.

(3a*S*,4*R*,6*S*,7*R*,7a*R*)-4-(hydroxymethyl)-6-methoxy-2,2dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-7-ol 13:

To the solution of **12** (8.0 g, 0.04 mol) in acetone (250 mL) was added 2,2-dimethoxypropane (6.07 mL, 0.05 mol) followed by catalytic amount of camphorsulfonic acid. After 12 h of stirring, the reaction mixture was concentrated under reduced pressure to ⁵ a colorless oil which on column chromatographic purification gave the pure compound **13** (5.78 g, 60 %) as a white semi solid. $[\alpha]_D^{28}$ +17.5 (*c* 9.8, MeOH); R_f 0.4 (EtOAc). Eluent for column chromatography: EtOAc/Hexane (30/20, v/v); IR (Neat): 3452, 3018, 2363, 1379, 1217 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ ¹⁰ 4.69 (d, 1H, *J* = 2.1), 4.19-4.16 (m, 2H), 4.08-3.96 (m, 1H), 3.87-3.70 (m, 3H), 3.38 (s, 3H), 3.10 (d, 1H, *J* = 6.3), 2.82 (d, 1H, *J* = 3.5); ¹³C NMR (75 MHz, CDCl₃): 109.5, 98.6, 76.1, 73.6, 69.5, 67.9, 62.2, 55.3, 27.6, 25.8; MS (ESI): *m/z* 235 (M⁺+H). Anal. Calcd for C₁₀H₁₈O₆: C, 51.27; H, 7.75; Found: C, ¹⁵ 51.34; H, 7.82.

((3a*S*,4*R*,6*S*,7*R*,7a*S*)-7-acetoxy-6-methoxy-2,2dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4yl)methyl acetate 14:

To the solution of **13** (2.03 g, 0.008 mol) in pyridine (10 mL) ²⁰ was added acetic anhydride (3.27 mL, 0.03 mol). After 12 h of stirring, the reaction mixture was concentrated under reduced pressure to a colorless oil which on column chromatographic purification gave the pure compound **14** (2.50 g, 91%) as a colorless gum. $[\alpha]_D^{28}$ +17.0 (*c* 11.8, MeOH); *R_f* 0.8 (1/1 ²⁵ EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (10/40, v/v); IR (Neat): 3433, 2995, 2364, 1735,

- 1377, 1236, 1036 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 4.92-4.90 (m, 1H), 4.85 (d, 1H, J = 3.5), 4.42- 4.28 (m, 3H), 4.24-4.15 (m, 2H), 3.39 (s, 3H), 2.14 (s, 3H), 2.10 (s, 3H), 1.52 (s, ³⁰ 3H), 1.34 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): 170.6, 170.3,
- 109.9, 96.9, 73.34, 73.31, 71.6, 65.4, 63.5, 55.3, 27.7, 26.2, 20.8, 20.7; MS (ESI): m/z 319 (M⁺+H). Anal. Calcd for $C_{14}H_{22}O_8$: C, 52.82; H, 6.97; Found: C, 52.90; H, 6.88.

((2*R*,3*R*,4*S*,5*R*,6*S*)-5-acetoxy-3,4-dihydroxy-6-³⁵ methoxytetrahydro-2H-pyran-2-yl)methyl acetate 15:

To compound 14 (2.20 g, 0.007 mol), 80 % acetic acid (25 mL) was added and stirred for 2 h at 80 °C. After completion of reaction (TLC), the acidic solution was concentrated under reduced pressure to give a crude product which was purified by

- ⁴⁰ column chromatography to yield compound **15** (1.80 g, 94 %) as a colorless gum. $R_f 0.2$ (1/1 EtOAc:Hexane). $[\alpha]_D^{28}$ = +99.5 (*c* 1.6, CHCl₃); Eluent for column chromatography: EtOAc/Hexane (25/25, v/v); IR (Neat): 3461, 3021, 1735, 1238, 1053, 756 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 4.98- 4.94 (m, 1H), 4.82 (d, 1H,
- ⁴⁵ J = 3.6), 4.32- 4.26 (m, 1H), 4.21- 4.15 (m, 1H), 3.92- 3.91 (m, 3H), 3.55 (bs, 1H), 3.31 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H); MS (ESI): m/z 279 (M⁺+H). Anal. Calcd for C₁₁H₁₈O₈: C, 47.48; H, 6.52; Found: C, 47.54; H, 6.61.

((2*S*,5*R*,6*S*)-5-acetoxy-6-methoxy-5,6-dihydro-2H-pyran-2-⁵⁰ yl)methyl acetate 16:

Compound 15 (1.37 g, 0.005 mol) was dissolved in dry toluene (200 mL) under nitrogen atmosphere and stirred for 30 min. at room temperature. Then triphenyl phosphine (5.28 g, 0.02 mol), iodoform (3.96 g, 0.01 mol) and imidazole (0.68 g, 0.01 mol) were successively added and the reaction mixture was heated to reflux for 2.5 h with vigorous heating. After cooling to room temperature, methanol and saturated solution of sodium bicarbonate were added. The organic layer was separated and aqueous layer was extracted with ether. The combined organic portion were dried over Na2SO4 and concentrated under vacuo to 60 give a crude product which was purified by column chromatography to yield compound 16 (1.80 g, 94 %) as a colorless. $R_f 0.8$ (1/1 EtOAc:Hexane). $[\alpha]_D^{28} = +1.1.2$ (c 1.6, CHCl₃); Eluent for column chromatography: EtOAc/Hexane 65 (7.5/42.5, v/v); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 5.82 (d, 1H, J = 11), 5.79 (d, 1H, J = 11), 5.32- 5.31 (m, 1H), 5.10 (d, 1H, J = 4.1), 4.39 (d, 1H, J = 2.1), 4.18 (d, 1H, J = 5.0), 3.50 (s, 3H), 2.12 (s, 3H), 2.09 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): 170.5, 127.8, 70 124.3, 95.9, 66.7, 66.5, 65.3, 56.1, 20.9, 20.8; MS (ESI): m/z 245 (M⁺+H). Anal. Calcd for C₁₁H₁₆O₆: C, 54.09; H, 6.60; Found: C, 54.17; H, 6.69

(2*S*,3*R*,6*S*)-6-(hydroxymethyl)-2-methoxy-3,6-dihydro-2H-pyran-3-ol 17:

75 To the stirred solution of 16 (1.80 g, 0.007 mol) in methanol, anhydrous K₂CO₃ (2.54 g, 0.2 mol) was added and allowed to stir for 30 min. After completion of reaction, methanol was evaporated in vacuo and residue was diluted with water. Aqueous layer was extracted with ethyl acetate (20 mL \times 3). The 80 combined organic extracts were washed with brine, and dried over Na₂SO₄. The organic fraction was concentrated in vacuo to give 17 (1.12 g, 95%) as white gum. $[\alpha]_D^{28} = +93.2$ (c 0.9, CHCl₃); R_f 0.2 (1/1 EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (40/10, v/v); IR (Neat): 3469, 85 2928, 1742, 1372, 1245, 1047 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 5.80 (d, 1H, J = 10.6), 5.69 (d, 1H, J = 10.6), 4.91 (d, 1H, J = 4.1), 4.21- 4.20 (m, 2H), 3.74- 3.57 (m, 2H), 3.53 (s, 3H), 2.38 (d, 1H, J = 11), 2.19 (bs, 1H); MS (ESI): m/z 161 (M⁺+H). Anal. Calcd for C₇H₁₂O₄: C, 52.49; H, 7.55; Found: C, 90 52.56; H, 7.64.

(2*S*,3*R*,6*S*)-6-((tert-butyldimethylsilyloxy)methyl)-2methoxy-3,6-dihydro-2H-pyran-3-ol 18:

To the stirred solution of **17** (0.19 g, 1.23 mmol) in dry DCM (5 mL), TBDMSCl (0.20 g, 1.35 mmol) and imidazole (0.13 g, 1.85 ⁹⁵ mmol) were added at 0 °C and allowed to stir for 30 minutes. After completion of reaction, it was diluted with water and extracted with dichloromethane (10 mL × 3). The combined organic extracts were washed with brine, and dried over Na₂SO₄. The organic fraction was concentrated in vacuo to give **18** (0.30 ¹⁰⁰ g, 95%) as colorless gum. $[\alpha]_D^{28}$ = -9.1 (*c* 1.5, CHCl₃); R_f 0.80 (1/4 EtOAc/Hexane). Eluent for column chromatography: EtOAc/Hexane (2.5/47.5, v/v); IR (Neat): 3447, 3021, 2359,

1216, 1056, 768 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 5.82 (d,

1H, J = 10.6), 5.73 (d, 1H, J = 10.6), 4.87 (d, 1H, J = 4.3), 4.20-4.09 (m, 2H), 3.72- 3.56 (m, 2H), 3.51 (s, 3H), 2.24 (d, 1H, J =11.1), 0.89 (s, 9H), 0.07 (s, 6H); ¹³C NMR (CDCl₃, 75MHz): δ 127.6, 127.3, 97.9, 77.6, 76.9, 76.3, 69.0, 65.4, 64.3, 55.9, 25.8, s 18.3, -5.33, -5.37; MS (ESI): m/z 275 (M⁺+H). Anal. Calcd for C₁₃H₂₆O₄Si: C, 56.90; H, 9.55 Found: C, 56.99; H, 9.63.

Compound 19:

To the solution of 18 (0.20 g, 0.73 mmol), 11 (0.31 g, 1.45 mmol) and PyBroP (0.68 g, 1.45 mmol) in DCM was DIPEA 10 (0.51 ml, 2.91 mmol), DMAP (0.09 g, 0.80 mmol) were added at 0 °C under argon atmosphere. After overnight stirring, it was diluted with water and extracted with dichloromethane (10 mL \times 3). The combined organic extracts were washed with brine, and dried over Na₂SO₄. The organic fraction was concentrated in 15 vacuo and purified by column chromatography to give 19 (0.30 g, 95%) as yellowish gum. $[\alpha]_D^{28} = +123.2$ (c 0.23, CHCl₃), R_f 0.3 (EtOAc). Eluent for column chromatography: EtOAc/Hexane (30/20, v/v); IR (Neat): 3426, 2931, 1664, 1249, 765 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.33 (d, 1H, J = 8.5), $_{20}$ 6.80 (d, 1H, J = 8.5), 5.03 (d, 1H, J = 2.9), 4.62 (dd, 1H, J = 4.4, 3.2), 4.36 (d, 1H, J = 5.8), 4.23 (d, 1H, J = 10.1), 4.17 (brs, 1H), 3.95- 3.91 (m, 2H), 3.84- 3.80 (m, 5H), 3.50 (s, 3H), 3.47- 3.42

(m, 1H), 0.90 (s, 9H), 0.08 (s, 6H); ¹³C NMR (CDCl₃, 75MHz): δ 172.5, 159.3, 130.4, 127.7, 113.9, 95.4, 72.3, 72.1, 67.2, 65.0, ²⁵ 56.4, 55.2, 43.0, 31.4, 25.8, -5.5; MS (ESI): *m/z* 466 (M⁺+H). Anal. Calcd for C₂₃H₃₅NO₇Si: C, 59.33; H, 7.58; N, 3.01. Found: C, 59.41; H, 7.67; N, 3.10.

Compound 20:

To the solution of **19** (0.05 g, 0.11 mmol) in THF, 1N HCl was ³⁰ added and stirred for 30 min. at room temperature. After completion of reaction, it was diluted with water. Aqueous layer was extracted with ethyl acetate (10 mL × 3). The combined organic extracts were washed with brine, and dried over Na₂SO₄. The organic fraction was concentrated in vacuo to give **20** (0.30 ³⁵ g, 95%) as white semi solid. $[\alpha]_D^{28}$ = +53.2 (*c* 0.35, MeOH). R_f 0.3 (0.2/9.8 MeOH/Chloroform); IR (Neat): 3416, 2920, 2367,

- 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.21 (d, 1H, J = 8.5), 6.83 (d, 1H, J = 8.5), 4.94 (d, 1H, J = 3.9), 4.59- 4.38 (m, 4H), 3.91- 3.87 (m, 2H), 3.86- 3.77 (m, 4H), 3.55-⁴⁰ 3.50 (m, 1H), 3.33 (s, 3H), 2.02 (s, 1H); ¹³C NMR (CDCl₃,
- ⁴⁰ 3.50 (m, 1H), 3.53 (s, 3H), 2.02 (s, 1H); ⁴⁰ C NMR (CDCl₃, 75MHz): δ 170.3, 158.6, 129.8, 128.9, 113.8, 97.3, 75.2, 72.7, 68.1, 62.1, 555.4, 55.2, 48.3; MS (ESI): *m*/*z* 352 (M⁺+H). Anal. Calcd for C₁₇H₂₁NO₇: C, 58.11; H, 6.02; N, 3.99. Found: C, 58.20; H, 6.10; N, 3.90.

45 Compound 22:

To a solution of **19** (0.05 g, 0.11 mmol) in dry THF, LAH (0.005 g, 0.15 mmol) was added at 0 $^{\circ}$ C and stirred for 1h at room temperature. After completion of reaction, it was quenched by water and extracted by ethyl acetate (5 mL × 3). The combined

50 organic portion were washed with brine, dried over Na₂SO₄ and concentrated under vacuo. Crude was purified by column chromatography to give **22** (0.04 g, 95%) as colourless oil. $[\alpha]_D^{28} = + 93.5$ (*c* 0.43, CHCl₃). R_f 0.4 (3/2EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (20/30, v/v); ⁵⁵ IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.26 (d, 2H, *J* = 8.5), 6.85 (d, 2H, *J* = 8.5), 5.26 (s, 1H), 4.90 (d, 1H, *J* = 4.3), 4.63 (t, 1H, *J* = 4.7), 4.26 (t, 1H, *J* = 7.8), 3.99- 3.94 (m, 2H), 3.89- 3.88 (m, 2H), 3.81 (s, 3H), 3.77- 3.68 (m, 2H), 3.31 (s, 3H), 3.29- 3.22 (m, ⁶⁰ 2H), 0.90 (s, 9H), 0.07 (s, 6H); MS (ESI): *m/z* 467 (M⁺+H). Anal. Calcd for C₂₃H₃₇NO₇Si: C, 59.07; H, 7.98; N, 3.00; Found: C, 59.13; H, 7.70; N, 3.10.

Compound 23:

To a solution of 22 (0.05 g, 0.11 mmol) in dry THF, LAH (0.012 65 g, 0.33 mmol) was added at 0 °C and refluxed for 3 days. After that, it was quenched by water and extracted by ethyl acetate (5 mL \times 3). The combined organic portion were washed with brine, dried over Na₂SO₄ and concentrated under vacuo. Crude was purified by column chromatography to give 23 (0.005 g, 70 10%) as colourless oil. $[\alpha]_D^{28} = +110.2$ (c 0.52, CHCl₃). R_f 0.3 (EtOAc). Eluent for column chromatography: EtOAc/Hexane (40/10, v/v); IR (Neat): 3420, 2920, 2361, 1612, 1504, 1246, 1031 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.26 (d, 2H, J = 8.5), 6.84 (d, 2H, J = 8.5), 4.62 (s, 1H), 4.61-4.24 (m, 1H), 4.18 $_{75}$ (t, 1H, J = 4.2), 4.02-4.00 (m, 3H), 3.99-3.90 (m, 3H), 3.89-3.84 (m, 1H), 3.83 (s, 3H), 3.69-3.64 (m, 1H), 3.49 (s, 3H), 3.41-3.34 (m, 1H), 2.92-2.30 (m, 1H), 0.90 (s, 9H), 0.06 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 159.1, 130.5, 128.3, 113.8, 98.1, 73.1, 71.6, 67.3, 65.9, 64.3, 61.3, 55.5, 55.2, 45.6, 31.9, 25.9, 22.7, -⁸⁰ 5.3; MS (ESI): m/z 470 (M⁺+H). Anal. Calcd for C₂₃H₃₉NO₇Si: C, 58.82; H, 8.37; N, 2.98; Found: C, 58.91; H, 8.43; N, 2.90.

Compound 24:

A solution of DIBAL-H (1.0 M in toluene, 0.62 mL, 0.62 mmol) was added to a cooled (0-5°C) solution of benzylamine (0.07 85 mL, 0.63 mmol) in THF (0.27 mL) under nitrogen. The mixture was allowed to warm up and stirred at RT for 2 h. To a solution of 19 (0.05 g, 0.11 mmol) in THF (0.40 mL) was added, under nitrogen at rt, the DIBAL-H-amine complexes (0.27 mL). After stirring at rt for 2 h, the reaction was cooled to 0°C, and then 90 quenched with H₂O (1.5 mL) and a 1 M aqueous solution of KHSO₄ (4 mL). The resulting mixture was extracted with CH₂Cl₂ (3×10 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under vacuo. The residue was purified by column chromatography to give 24 95 (0.05 g, 85%). $[\alpha]_{D}^{28} = +106.3$ (c 0.85, CHCl₃). R_f 0.5 (1.5/3.5 EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (25/25, v/v); IR (Neat): 3370, 2925, 2363, 1657, 1518, 1251 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.64 (t, 1H, J = 5.2), 7.32-7.22 (m, 3H), 7.17-7.13 (m, 4H), 6.78 (d, 1H, J =100 8.5), 4.62 (d, 1H, J = 3.6), 4.53- 4.46 (m, 1H), 4.32 (t, 1H, J =7.4), 4.24- 4.10 (m, 3H), 3.94- 3.83 (m, 4H), 3.78- 3.74 (s, 4H), 3.71- 3.68 (m, 1H), 3.42 (s, 3H), 3.23- 3.21 (m, 1H), 0.90 (s, 9H), 0.07 (s, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 170.4, 159.3, 137.7, 130.8, 128.5, 127.6, 127.3, 114.0, 98.0, 74.4, 70.2, 68.1,

65.9, 64.2, 62.4, 55.4, 55.2, 47.6, 43.3, 25.9, -5.34; MS (ESI): m/z 569 (M⁺+H). Anal. Calcd for C₃₀H₄₄N₂O₇Si: C, 62.91; H, 7.74; N, 4.89; Found: C, 62.90; H, 7.81; N, 4.96.

(3a*R*,4*S*,6*S*,7*R*,7a*R*)-4-(iodomethyl)-6-methoxy-2,2s dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-7-ol 25:

To the solution of **12** (0.10 g, 0.43 mmol) in dry toluene (10 mL), triphenyl phosphine (0.15 g, 0.59 mmol), iodine (0.16 g, 0.64 mol) and imidazole (0.08 g, 1.28 mmol) were successively added and the reaction mixture was heated at 60 $^{\circ}$ C for 2.5 h

- ¹⁰ with vigorous heating. After cooling to room temperature, organic layer was separated and aqueous layer was extracted with ether. The combined organic portion were dried over Na₂SO₄ and concentrated under vacuo to give a crude product which was purified by column chromatography to yield
- ¹⁵ compound **25** (0.11 g, 75 %) as a colorless oil. $[\alpha]_D^{28} = +119$ (*c* 1.0, CHCl₃); R_f 0.8 (1/1EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (5/45, v/v); IR (Neat): 3445, 2918, 1638, 1216, 1066, 761cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 4.69 (d, 1H, *J* = 3.8), 4.26- 4.19 (m, 2H), 4.08- 4.04 (m, 1H),
- 20 3.79- 3.76 (m, 1H), 3.44 (s, 3H), 3.28- 3.24 (m, 2H), 2.69 (br s, 1H), 1.42 (s, 3H), 1.28 (s, 3H); ^{13}C NMR (75 MHz, CDCl₃): 109.5, 98.2, 75.6, 73.4, 69.1, 55.4, 27.3, 25.6, 2.7; MS (ESI): m/z 345 (M⁺+H). Anal. Calcd for $C_{10}H_{17}IO_5$: C, 34.90; H, 4.98; Found: C, 34.98; H, 4.90.

25 (3a*R*,4*S*,6*S*,7*R*,7a*S*)-4-(iodomethyl)-6-methoxy-2,2dimethyltetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-7-yl acetate 26:

As described for **13**, compound **26** was prepared from compound **25** (0.10 g, 0.29 mmol), dry pyridine (2 mL) and acetic ³⁰ anhydride (0.05 mL, 0.58 mmol). Crude product was purified by column chromatography to yield compound **26** (0.10g, 95%) as a colorless. $[\alpha]_D^{28}$ = +19.1 (*c* 1.5, CHCl₃); R_f 0.6 (1/4 EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (5/45, v/v); IR (Neat): 3416, 2920, 2367, 1608, ³⁵ 1508, 1246, 1034 cm^{-1. 1}H NMR (300 MHz, CDCl₃): δ 4.91(dd, 1H, *J* = 10.3, 6.6), 4.84 (d, 1H, *J* = 3.4), 4.37- 4.30 (m, 2H), 4.11 (d, 1H, *J* = 7.5), 3.43 (s, 3H), 3.36- 3.33 (m, 2H), 2.13 (s, 3H), 1.52 (s, 3H), 1.35 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): 170.4, 109.7, 97.3, 73.8, 73.4, 71.5, 68.2, 55.6, 27.8, 26.3, 20.9, 2.1;

⁴⁰ MS (ESI): *m/z* 387 (M⁺+H). Anal. Calcd for C₁₂H₁₉IO₆: C, 37.32; H, 4.96; Found: C, 37.40; H, 4.90.

(2*S*,3*R*,4*S*,5*R*)-4,5-dihydroxy-6-(iodomethyl)-2methoxytetrahydro-2H-pyran-3-yl acetate 27:

As described for **14**, compound **27** was prepared from compound ⁴⁵ **26** (0.01 g, 0.25 mmol), 80% acetic acid. Crude product was purified by column chromatography to yield compound **27** (0.07 g, 85 %) as a colorless. R_f 0.2 (1/1 EtOAc:Hexane). $[\alpha]_D^{28}$ = +87.5 (*c* 1.1, CHCl₃); Eluent for column chromatography: EtOAc/Hexane (25/25, v/v); IR (Neat): 3416, 2920, 2367, 1608,

⁵⁰ 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 5.01 (dd, 1H, *J* = 10.3, 6.6), 4.88 (d, 1H, *J* = 3.4), 4.15 (d, 1H, *J* = 2.5), 4.02- 3.94 (m, 2H), 3.45 (s, 3H), 3.36 (d, 2H, J = 6.9), 3.26 (bs, 2H), 2.16 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): 171.8, 97.3, 71.0, 70.5, 70.3, 68.3, 55.6, 21.1, 2.7; MS (ESI): m/z 346 (M⁺+H). ⁵⁵ Anal. Calcd for C₉H₁₅IO₆: C, 31.23; H, 4.37; Found: C, 31.31; H, 4.30.

(2*S*,3*R*,6*S*)-6-(iodomethyl)-2-methoxy-3,6-dihydro-2H-pyran-3-yl acetate 28:

As described for **15**, compound **28** was prepared from compound ⁶⁰ **27** (1.8 g, 0.005 mol), PPh₃ (7.56 g, 0.02 mol), iodoform (4.24 g, 0.01 mol) and imidazole (1.41 g, 0.003 mol). Crude product was purified by column chromatography to yield compound **28** (1.22 g, 68 %) as a colorless oil. [α]_D²⁸= +103.5 (*c* 1.8, CHCl₃); R_f 0.8 (1/1 EtOAc:Hexane). Eluent for column chromatography: ⁶⁵ EtOAc/Hexane (7.5/42.5, v/v); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 5.88- 5.73 (m, 2H), 5.30- 5.27 (m, 1H), 5.11 (d, 1H, *J* = 3.9), 4.22- 4.21 (m, 1H), 3.49 (s, 3H), 3.33- 3.20 (m, 2H), 2.12 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): 170.4, 129.9, 124.2, 96.2, ⁷⁰ 67.0, 66.4, 56.0, 20.9, 8.5; MS (ESI): *m/z* 312 (M⁺+H). Anal. Calcd for C₉H₁₃IO₄: C, 34.63; H, 4.20; Found: C, 34.70; H, 4.28.

(2*S*,3*R*,6*S*)-6-(iodomethyl)-2-methoxy-3,6-dihydro-2H-pyran-3-ol: 29

To the stirred solution of 28 (0.85 g, 2.71 mmol) in methanol, 75 anhydrous K₂CO₃ (0.56 g, 4.06 mmol) was added and allowed to stir for 30 min. After completion of reaction, methanol was evaporated in vacuo and residue was diluted with water. Aqueous layer was extracted with ethyl acetate (20 mL \times 3). The combined organic extracts were washed with brine, and dried 80 over Na₂SO₄. The organic fraction was concentrated in vacuo and crude product was purified by column chromatography to vield compound **29** (0.57 g, 78%) as a colorless gum. $\left[\alpha\right]_{D}^{28}$ 59.3 (c 0.32, MeOH). R_f 0.5 (1.5/8.5 EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (6/44, v/v); IR (Neat): 85 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): *δ* 5.85- 5.72 (m, 2H), 5.72- 5.68 (m, 1H), 4.91 (d, 1H, J = 4.2), 4.21- 4.20 (m, 2H), 3.53 (s, 3H), 3.32- 3.18 (m, 2H); ¹³C NMR (75 MHz, CDCl₃): 128.8, 127.9, 98.4, 67.0, 64.0, 56.1, 9.0; MS (ESI): m/z 270 (M⁺+H). Anal. Calcd for C₇H₁₁IO₃: 90 C, 31.13; H, 4.11; Found: C, 31.21; H, 4.20.

Compound 21:

As described for **19**, compound **21** was prepared from compound **29** (0.10 g, 0.37 mmol), **11** (0.09 g, 0.44 mmol), PyBroP (0.34 g, 0.74 mmol), DIPEA (0.25 mL, 1.48 mmol) and DMAP (0.05 g, 95 0.40 mmol). Crude product was purified by column chromatography to yield compound **21** (1.22 g, 72%) as a white solid. [*a*]_D²⁸= 49.3 (*c* 0.02, MeOH); R_f 0.5 (EtOAc). Eluent for column chromatography: EtOAc/Hexane (30/20, v/v); IR (Neat): 3345, 2926, 2365, 1750, 1247, 1033 cm⁻¹. ¹H NMR (300 MHz, 100 CDCl₃): δ 7.20 (d, 2H, *J* = 8.5), 6.85 (d, 2H, *J* = 8.5), 4.99 (d, 1H, *J* = 4.1), 4.65- 4.63 (m, 1H), 4.43 (s, 2H), 4.32 (d, 1H, *J* = 7.1), 3.79 (s, 3H), 3.57- 3.47 (m, 2H), 3.41 (s, 3H), 3.39- 3.27 (m, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 170.3, 158.8, 131.7, 129.8, 128.9, 124.9, 114.0, 97.3, 75.5, 72.3, 71.6, 55.7, 55.3, 48.8, 5.9; MS (ESI): *m/z* 462 (M⁺+H). Anal. Calcd for C₁₇H₂₀INO₆: C, 44.27; H, 4.37; N, 3.04; Found: C, 44.33; H, ${}_{5}$ 4.43; N, 3.11.

Compound 30 a:

As described for **24**, compound **30a** was prepared from compound **21** (0.05 g, 0.11 mmol), benzylamine (0.07 mL, 0.63 mmol) in THF (0.27 mL), DIBAL-H (0.62 mL, 0.62 mmol).

- ¹⁰ Crude product was purified by column chromatography to give **30a** (0.05 g, 85%) as gum. $[\alpha]_D^{28}$ = + 63.2 (*c* 0.03, CHCl₃) R_f 0.5 (1.5/3.5 EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (25/25, v/v); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃+ CD₃OD): δ
- ¹⁵ 7.20- 7.17 (m, 3H), 7.13- 7.10 (m, 2H), 7.01 (d, 2H, J = 6.2), 6.70 (d, 2H, J = 8.5), 4.47 (d, 1H, J = 3.5), 4.45- 4.17 (m, 1H), 4.25- 4.15 (m, 1H), 4.15- 4.05 (m, 1H), 4.00- 3.95 (m, 1H), 3.95-3.75 (m, 3H), 3.68 (s, 3H), 3.41- 3.32 (m, 4H), 3.24- 3.13 (m, 1H), 3.10 (t, 2H, J = 8.1); ¹³C NMR (75 MHz, CDCl₃): δ 170.1,
- ²⁰ 159.5, 128.6, 127.8, 127.7, 127.5, 127.3, 114.3, 97.2, 74.9, 67.6, 67.5, 58.4, 56.0, 55.3, 53.5, 37.1, 4.7; MS (ESI): m/z 569 (M⁺+H). Anal. Calcd for C₂₄H₂₉IN₂O₆: C, 50.71; H, 5.14; N, 4.93; Found: C, 50.70; H, 5.20; N, 4.90.

Compound 30b:

- ²⁵ As described for **24**, compound **30b** was prepared from compound **21** (0.05 g, 0.11 mmol), cyclohexylamine (0.07 mL, 0.63 mmol) in THF (0.27 mL), DIBAL-H (0.62 mL, 0.62 mmol). Crude product was purified by column chromatography to yield compound **30b** (0.05 g, 85%) as a light yellow semi solid.
- ³⁰ $[\alpha]_D^{28}$ = 52.8 (*c* 0.03, CHCl₃); R_f 0.5 (3/2EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (25/25, v/v); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃+ CD₃OD): δ 7.16 (d, 1H, *J* = 8.5), 6.78 (d, 1H, *J* = 8.5), 4.49 (s, 1H), 4.15- 4.01 (m, 3H), 3.83- 3.74 (m,
- ³⁵ 3H), 3.50 (s, 3H), 3.44- 3.25 (m, 2H), 3.09- 3.06 (m, 2H), 1.77- 1.73 (m,1H), 1.59- 1.49 (m, 5H), 1.30- 1.09 (m, 4H); ¹³C NMR (75 MHz, CDCl₃+MeOH): δ 169.1, 158.9, 130.3, 126.8, 113.5, 97.7, 78.1, 69.2, 67.4, 65.0, 61.7, 55.1, 54.5, 49.2, 48.8, 48.3, 47.9, 47.5, 47.0, 46.6, 31.7, 31.5, 24.8, 24.0, 5.8; MS (ESI): *m/z*
- ⁴⁰ 561 (M⁺+H). Anal. Calcd for C₂₃H₃₃IN₂O₆: C, 49.29; H, 5.94; N, 5.00; Found: C, 49.37; H, 5.88; N, 5.09.

Compound 30c:

As described for **24**, compound **30c** was prepared from compound **19** (0.5 g, 0.11 mmol), phenethyl amine (0.08 mL, ⁴⁵ 0.64 mmol) in THF (0.27 mL) and DIBAL-H (0.62 mL, 0.62 mmol). Crude product was purified by column chromatography to yield compound **30c** (0.05 g, 85%) as a white semi solid.

- $[\alpha]_D^{28}$ = +181.4 (*c* 0.03, CHCl₃) R_f 0.5 (3/2 EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (25/25, v/v);
- ⁵⁰ IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃+ CD₃OD): *δ* 7.33- 7.19 (m, 5H), 7.12

60 Compound 32a:

C, 51.62; H, 5.43; N, 4.90.

To a stirred solution of 30a (0.05 g, 0.08 mmol) in acetonitrilewater (1.30 mL, 15:1) was added Mo(CO)₆ (0.03 g, 0.11 mmol) and the mixture was heated at reflux under nitrogen atmosphere for 5 h. It was concentrated under vacuum and the residue was 65 used in next reaction without further purification. The crude was taken in pyridine (1 mL) and DMAP (cat.) and 3 drops of acetic anhydride were added at 0 °C, and the mixture was kept at room temperature for 12 h. After completion of reaction, pyridine was evaporated under vacuo to yield the crude which was purified by ⁷⁰ column chromatography to give compound **32a** (0.04 g, 75 %) as a white semi solid. $[\alpha]_D^{28}$ +55.8 (c 0.9, CHCl₃); R_f 0.5 (1/4 EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (6/44, v/v); IR (Neat): 3416, 2920, 2368, 1610, 1503, 1240, 1032 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.30 (d, $_{75}$ 2H, J = 6.4), 7.24-7.20 (m, 4H), 7.05-6.95 (m, 1H), 6.86 (d, 2H, J = 6.4), 6.75 (m, 1H), 4.93-4.86 (m, 2H), 4.68 (d, 1H, J = 12.1), 4.44 (d, 1H, J = 12.1), 4.38- 4.32 (m, 2H), 3.74 (s, 3H), 3.72-3.69 (m, 1H), 3.59- 3.58 (m, 1H), 3.42-3.38 (m, 2H), 3.35- 3.31 (m, 4H), 3.14-3.11 (m, 1H), 2.12 (s, 3H), 2.07 (s, 3H); ¹³C NMR 80 (75 MHz, CDCl₃): δ 171.4, 170.1, 169.2, 159.5, 128.6, 128.5, 127.8, 127.7, 127.5, 127.3, 114.4, 97.2, 74.9, 67.6, 67.5, 58.4, 56.0, 55.3, 53.5, 37.1, 21.7, 20.9, 4.7; MS (ESI): m/z 655 (M⁺+H). Anal. Calcd for C₂₈H₃₅IN₂O₈: C, 51.38; H, 5.39; N, 4.28; Found: C, 51.45; H, 5.47; N, 4.35.

85 Compound 32b:

As described for 32a, compound 32b was prepared from compound **30b** (0.05 g, 0.09 mmol), Mo(CO)₆ (0.04 g, 0.13 mmol), acetonitrile: water (1.5 ml, 15:1) and acetic anhydride (0.1 mL). Crude product was purified by column 90 chromatography to yield compound 32b (0.04 g, 78%) as a white semisolid. $R_f 0.5$ (1:4 EtOAc:Hexane). $[\alpha]_D^{28} = +65.3$ (c 0.7, CHCl₃); Eluent for column chromatography: EtOAc/Hexane (10/40, v/v); IR (Neat): 3420, 2925, 2351, 1615, 1512, 1246, 1038 cm⁻¹. ¹H NMR (300 MHz, CDCl₂): δ 7.29 (d, 2H, J = 6.5), 95 6.85 (d, 2H, J = 6.5), 4.93-4.90 (m, 1H), 4.86 (d, 1H, J = 2.9), 4.68 (d, 1H, J = 12.1), 4.56 (d, 1H, J = 12.1), 4.38-4.32 (m, 2H), 3.74 (s, 3H), 3.71-3.69 (m, 1H), 3.58-3.57 (m, 2H), 3.42 (t, 1H, J = 1.8), 3.40 (s, 3H), 3.39-3.30 (m, 1H), 3.14-3.09 (m, 1H), 2.23 (m, 1H), 2.23 (s, 3H), 2.11 (s, 3H). 1.26-1.18 (m, 10H); ^{13}C 100 NMR (75 MHz, CDCl₃): 171.4, 170.1, 169.2, 159.4, 128.5, 127.3, 114.2, 97.1, 74.8, 67.6, 67.4, 58.3, 55.9, 55.2, 53.4, 37.0, 29.2, 29.0, 27.1, 24.7, 22.6, 21.6, 20.9, 4.7; MS (ESI): m/z 647 (M^++H) . Anal. Calcd for $C_{27}H_{39}IN_2O_8$: C, 50.16; H, 6.08; N, 4.33; Found: C, 50.22; H, 6.15; N, 4.41.

Compound 34:

To a stirred solution of **21** (0.05 g, 0.11 mmol) in acetonitrilewater (1.80 mL, 15:1) was added $Mo(CO)_6$ (0.04 g, 0.16 mmol) and the mixture was heated at reflux under nitrogen atmosphere

- ⁵ for 5 h. It was concentrated under vacuum and the residue was used in next reaction without further purification. The crude was taken in pyridine (1 mL) and DMAP (cat.) and 3 drops of acetic anhydride were added at 0 °C, and the mixture was kept at room temperature for 12 h. After completion of reaction, pyridine was
- ¹⁰ evaporated under vacuo to yield the crude which was purified by column chromatography to give compound **34** (0.04 g, 72 %) as a white semi solid. $[\alpha]_D^{28}= 28.7$ (*c* 0.8, CHCl₃); R_f 0.7 (1/1EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (6/44, v/v); IR (Neat): 3416, 2920, 2367, 1608,
- ¹⁵ 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.29 (d, 2H, *J* = 6.5), 6,86 (d, 2H, *J* = 6.5), 4.92- 4.85 (m, 2H), 4.65 (d, 1H, *J* = 12.1), 4.46- 4.40 (m, 1H), 4.38- 4.32 (m, 2H), 3.74 (s, 3H), 3.62- 3.51 (m, 1H), 3.46- 3.38 (m, 1H), 3.33 (s, 3H), 3.15-3.05 (m 1H), 2.11 (s, 3H), 2.07 (s, 3H); ¹³C NMR (75 MHz,
- ²⁰ CDCl₃): δ 171.4, 170.1, 169.1, 159.4, 128.5, 127.3, 114.2, 97.1, 74.8, 67.5, 67.4, 58.3, 55.9, 55.2, 53.4, 36.9, 22.5, 21.6, 20.8, 4.6; MS (ESI): *m/z* 548 (M⁺+H). Anal. Calcd for C₂₁H₂₆INO₈: C, 46.08; H, 4.79; N, 2.56; Found: C, 46.15; H, 4.86; N, 2.63.

Compound 36:

- $_{25}$ To a stirred suspension of zinc dust (0.08 g, 0.15 mmol) and NH₄Cl (1.9 mL) in THF (1.9 mL) was added compound **34** (0.08 g, 0.15 mmol) and refluxed for 1.5 h. After completion of reaction, it was diluted with water. The resulting mixture was extracted with ethyl acetate (5×10 mL). The combined organic
- ³⁰ layers were washed with brine, dried over Na₂SO₄ and concentrated under vacuo to give crude as oil. The oil without further purification was taken in DCM (10 mL) and (carbethoxymethylene)triphenylphosphorane (0.04 g, 0.13 mmol) was added at 0°C. After overnight stirring, solvent was
- ³⁵ evaporated under vacuo to give crude which on column purification yielded **36** (0.04 g, 65%) as a colorless oil. R_f 0.8 (1/1EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (6/44, v/v); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.23 (d,
- ⁴⁰ 1H, J = 6.3), 6.84 (d, 2H, J = 6.3), 6.70- 6.66 (m, 1H), 5.88- 5.76 (m, 1H), 5.75- 5.70 (m, 1H), 5.32- 5.27 (m, 3H), 5.24- 5.06 (m, 1H), 4.64 (d, 1H, J = 12.4), 4.22- 4.19 (m, 3H), 3.74 (s, 3H), 2.09 (s, 3H), 1.98 (s, 3H), 1.23 (t, 3H, J = 5.4); ¹³C NMR (75 MHz, CDCl₃): 171.6, 171.4, 169.2, 165.2, 159.5, 141.6, 131.6,
- ⁴⁵ 128.4, 127.2, 124.7, 119.9, 114.5, 78.7, 70.3, 60.9, 55.3, 45.5, 29.6, 21.9, 20.8, 14.2; MS (ESI): *m*/*z* 460 (M⁺+H). Anal. Calcd for C₂₄H₂₉NO₈: C, 62.73; H, 6.36; N, 3.05; Found: C, 62.81; H, 6.43; N, 3.13.

((3aR,4R,6S,6aR)-6-methoxy-2,2-50 dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 38:

As described for **12**, compound **38** was prepared from compound **37** (0.52 g, 3.16 mmol), 2,2-DMP (0.39 g, 3.80 mmol) and

acetone (40 mL). Crude product was purified by column chromatography to yield compound **38** (0.05 g, 78%) as a ⁵⁵ colorless. R_f 0.5 (1/1 EtOAc:Hexane). $[\alpha]_D^{28}$ = -72.5 (*c* 0.8, MeOH); Eluent for column chromatography: EtOAc/Hexane (13/37, v/v); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 4.62 (d, 1H, *J* = 5.7), 4.51- 4.47 (m, 1H), 4.29- 4.25 (m, 1H), 3.82- 3.76 (m, 1H), 3.71- 60 3.66 (m, 2H), 3.46 (s, 3H), 2.71 (d, 1H, *J* = 5.5), 1.54 (s, 3H), 1.37 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): 109.8, 101.3, 73.0, 72.8, 68.4, 61.8, 55.8, 26.5, 25.2; MS (ESI): *m/z* 205 (M⁺+H). Anal. Calcd for C₉H₁₆O₅: C, 52.93; H, 7.90; Found: C, 52.83; H, 7.98.

65 ((3aR,4R,6S,6aR)-6-methoxy-2,2dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl acetate 39:

As described for **13**, compound **39** was prepared from compound **38** (0.11 g, 0.55 mmol), acetic anhydride (0.10 mL, 1.11 mmol). ⁷⁰ Crude product was purified by column chromatography to yield compound **39** (0.12 g, 95 %) as a colorless gum. $[\alpha]_D^{28}$ = -13.52 (*c* 7.5, MeOH); R_f 0.6 (1/4EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (4/46, v/v); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm^{-1.} ¹H NMR (300 MHz, ⁷⁵ CDCl₃): δ 4.91- 4.88 (m, 1H), 4.74 (d, 1H, *J* = 6.1), 4.57- 4.54 (m, 1H), 4.31 (d, 1H, *J* = 7.1), 3.81 (d, 1H, *J* = 2.2), 3.77 (d, 1H, *J* = 2.25), 3.41 (s, 3H), 2.16 (s, 3H), 1.54 (s, 3H), 1.33 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): 170.1, 110.1, 98.5, 73.4, 71.5, 69.9, 62.1, 55.4, 26.2, 25.1, 21.0; MS (ESI): *m/z* 247 (M⁺+H). Anal. ⁸⁰ Calcd for C₁₁H₁₈O₆: C, 53.65; H, 7.37; Found: C, 53.71; H, 7.45.

((2*R*,3*S*,4*R*,5*S*)-3,4-dihydroxy-5-methoxytetrahydrofuran-2yl)methyl acetate 40:

As described for **14**, compound **40** was prepared from compound **39** (0.5 g, 2.03 mmol) and 80% acetic acid (10 mL). Crude ⁸⁵ product was purified by column chromatography to yield compound **40** (0.3 g, 81 %) as a colorless gum. $[\alpha]_D^{28}$ = -5.16 (*c* 18.5, MeOH); R_f 0.5 (EtOAc). Eluent for column chromatography: EtOAc/Hexane (25/25, v/v); IR (Neat): 3422, 2930, 1733, 1244, 1069 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ ⁹⁰ 4.96 (t, 1H, *J* = 2.5), 4.70 (d, 1H, *J* = 2.2), 4.00- 3.97 (m, 1H), 3.91- 3.87 (m, 1H), 3.81- 3.80 (m, 2H), 3.40 (s, 3H), 2.91 (d, 1H, *J* = 8.1), 2.63 (d, 1H, *J* = 10.2), 2.15 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): 169.9, 98.8, 71.7, 68.6, 64.7, 63.1, 55.5. 21.0; MS (ESI): *m/z* 207 (M⁺+H). Anal. Calcd for C₈H₁₄O₆: C, 46.60; H, ⁹⁵ 6.84; Found: C, 46.69; H, 6.92.

((2S,5S)-5-methoxy-2,5-dihydrofuran-2-yl)methyl acetate 41:

As described for **15**, compound **41** was prepared from compound **40** (0.52 g, 2.54 mmol), PPh₃, (2.66 g, 10.16 mmol), iodoform (2.00 g, 5.08 mmol) and imidazole (0.34 g, 5.08 mmol). Crude ¹⁰⁰ product was purified by column chromatography to yield compound **41** (0.26 g, 62%) as a colorless. R_f 0.8 (1/1 EtOAc:Hexane). $[\alpha]_D^{28}$ = - 41.5 (*c* 0.4, MeOH); Eluent for column chromatography: EtOAc/Hexane (7.5/42.5, v/v); IR (Neat): 3416, 2920, 2367, 1608, 1508, 1246, 1034 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 6.10-6.00 (m, 2H), 4.94 (t, 1H, J = 3.1), 4.89 (d, 1H, J = 2.3), 4.13 (dd, 1H, J = 13.0, 2.7), 3.83 (d,1H, J = 13.3), 3.43 (s, 3H), 2.09 (s, 3H); ¹³C NMR (75 MHz, 5 CDCl₃): 170.6, 130.7, 125.0, 94.0, 63.3, 61.2, 55.7, 21.1; MS (ESI): m/z 173 (M⁺+H). Anal. Calcd for C₈H₁₂O₄: C, 55.81; H, 7.02; Found: C, 55.90; H, 7.10.

((2S,5S)-5-methoxy-2,5-dihydrofuran-2-yl)methanol 42:

As described for **16**, compound **42** was prepared from compound ¹⁰ **41** (0.5 g, 2.89 mmol) and anhy. K₂CO₃ (0.59 g, 4.33 mmol). Crude product was purified by column chromatography to yield compound **42** (0.29 g, 78%) as a colorless gum. R_f 0.5 (1/1EtOAc:Hexane). $[\alpha]_D^{28}$ = -6.24 (*c* 18.5, CHCl₃) Eluent for column chromatography: EtOAc/Hexane (12.5/47.5, v/v); IR

- ¹⁵ (Neat): 3408, 2924, 2357, 1598, 1218, 770 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 6.16- 6.10 (m, 1H), 5.88 (dd, 1H, J = 10.0, 3.6), 4.82 (d,1H, J = 2.7), 4.11- 4.06 (m, 1H), 3.81- 3.77 (m, 2H), 3.43 (s, 3H), 2.35 (d, 1H, J = 6.5); ¹³C NMR (75 MHz, CDCl₃): 129.2, 128.2, 94.2, 64.2, 61.4, 55.6; MS (ESI): m/z 131 (M⁺+H).
- ²⁰ Anal. Calcd for C₆H₁₀O₃: C, 55.37; H, 7.74; Found: C, 55.45; H, 7.82.

Compound 43:

As described for **19**, compound **43** was prepared from compound **42** (0.05 g, 3.84 mmol), **11** (1.21 g, 5.76 mmol), PyBroP (3.58 g, 25 7.68 mmol), DIPEA (2.66 mL, 15.36 mmol) and DMAP (0.52g,

- 4.22 mmol). Crude product was purified by column chromatography to yield compound **43** (0.07 g, 62%) as a white gum. $[\alpha]_D^{28}$ = -53.85 (*c* 0.13, CHCl₃). R_f 0.4 (EtOAc). Eluent for column chromatography: EtOAc/Hexane (25/25, v/v); IR (Neat):
- ³⁰ 3294, 2932, 2370, 1604, 1248, 1027, 836 cm⁻¹. ¹H NMR (300 MHz, (CD₃)₂CO): δ 7.38 (d, 2H, *J* = 8.5), 6.92 (d, 2H, *J* = 8.5), 4.68 (s, 1H), 4.61 (d, 1H, *J* = 7.4), 4.47 (d, 1H, *J* = 8.4), 4.12-4.08 (m, 2H), 3.96-3.90 (m, 2H), 3.81-3.78 (m, 5H), 3.41 (s, 3H); ¹³C NMR (75 MHz, (CD₃)₂CO): δ 159.3, 130.3, 128.7, ³⁵ 113.6, 95.8, 72.0, 70.3, 56.4, 54.6, 54.4, 38.3; MS (ESI): *m/z* 322

 (M^++H) . Anal. Calcd for $C_{16}H_{19}NO_6$: C, 59.81; H, 5.96; N, 4.36; Found: C, 59.90; H, 5.90; N, 4.45.

(2*R*,3*R*,4*S*,5*R*,6*S*)-4,5-bis(benzyloxy)-2-((tertbutyldimethylsilyloxy)methyl)-6-methoxytetrahydro-2H-40 pyran-3-ol 48:

To the stirred solution of **47** (0.79 g, 2.11 mmol) in dry DCM (15 mL), TBDMSCl (0.35 g, 2.32 mmol) and imidazole (0.29 g, 4.22 mmol) were added at 0 °C and allowed to stir for 30 minutes. After completion of reaction, it was diluted with water ⁴⁵ and extracted with dichloromethane (10 mL × 3). The combined organic extracts were washed with brine, and dried over Na₂SO₄. The organic fraction was concentrated in vacuo to give **48** (1.0 g, 97 %) as colourless gum. $[\alpha]_D^{28}$ = +58.8 (*c* 0.45, MeOH); R_f 0.5 (1:1 EtOAc:Hexane). Eluent for column chromatography: ⁵⁰ EtOAc/Hexane (6/44, v/v); IR (Neat): 3453, 2927, 2365, 1218,

1055, 767 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.40- 7.29 (m,

(2*R*,3*R*,4*R*,5*R*,6*S*)-4,5-bis(benzyloxy)-2-((tert-60 butyldimethylsilyloxy)methyl)-6-methoxytetrahydro-2H-

pyran-3-yl methanesulfonate 49:

To the stirred solution of 48 (1.0 g, 2.10 mmol) in dry DCM (25 mL), MsCl (0.19 mL, 2.50 mmol) and Et₃N (0.52 mL, 0.38 mmol) were added at 0 °C and allowed to stir for 1h. After 65 completion of reaction, it was diluted with water and extracted with dichloromethane (10 mL \times 3). The combined organic extracts were washed with brine, and dried over Na₂SO₄. The organic fraction was concentrated in vacuo to give 49 (0.95 g, 80 %) as colourless gum. $[\alpha]_D^{28} = +90.2$ (c 0.45, MeOH); R_f 0.5 (1/4 70 EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (5/45, v/v); IR (Neat): 3021, 2927, 2858, 2365, 1360, 1176, 767 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ7.36-7.34 (m, 10H), 5.06 (d, 1H, J = 10.9), 4.98- 4.72 (m, 2H), 4.67- 4.63 (m, 2H), 4.47 (t, 1H, J = 9.5), 4.06- 3.94 (m, 2H), 3.82- 3.72 (m, ⁷⁵ 1H), 3.42 (s, 3H), 2.86 (s, 3H), 0.92 (s, 9H), 0.09 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): *δ* 137.9, 137.6, 128.5, 128.4, 128.1, 127.7, 97.2, 80.3, 78.8, 78.1, 75.4, 73.3, 70.2, 62.1, 55.1, 38.5, 25.8, 18.2, -5.4; MS (ESI): m/z 589 (M⁺+Na). Anal. Calcd for C₂₈H₄₂O₈SSi: C, 59.34; H, 7.47; Found: C, 59.39; H, 7.51.

80 (2R,3R,4R,5R,6S)-4,5-bis(benzyloxy)-2-(hydroxymethyl)-6methoxytetrahydro-2H-pyran-3-yl methanesulfonate 50:

To a cooled solution of 49 (0.86 g, 1.52 mmol) in dry THF (25 mL), solution of TBAF (1.0M in THF, 0.56 mL) was added, and allowed to stir for 30 min. After completion of the reaction, 85 mixture was concentrated in vacuo; the residue was diluted with ethyl acetate. The combined organic layer was washed with water followed by brine. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under vacuum to colourless oil, which on column chromatographic purification gave the pure ⁹⁰ compound **50** as white gum (0.64 g, 95 %). $[\alpha]_D^{28} = +77.5$ (c 0.6, MeOH); R_f 0.3 (1.5:3.5 EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (15/35, v/v); IR (Neat): 3488, 2921, 2365, 1458, 1354, 1172, 1099, 1039, 954, 758 cm⁻¹. ¹H NMR (300 MHz, CDCl₃): δ 7.32 (m, 10H), 5.08 (d, 1H, J = 95 16.7), 4.78- 4.61 (m, 4H), 4.47 (t, 1H, J = 14.3), 4.04 (t, 1H, J = 14.3), 3.95- 3.88 (m, 1H), 3.79- 3.68 (m, 2H), 3.59 (dd, 1H, J = 14.2, 5.3), 3.37 (s, 3H), 2.79 (s, 3H), 2.52 (br s, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 137.8, 137.4, 128.5, 128.4, 128.2, 127.8, 127.7, 97.6, 80.1, 78.4, 77.6, 75.6, 73.2, 69.5, 60.3, 55.4, 38.2. 100 MS (ESI): m/z 475 (M⁺+Na). Anal. Calcd for C₂₂H₂₈O₈S: C, 58.39; H, 6.24; Found: C, 58.45; H, 6.30.

((2*S*,3*R*,4*S*)-3,4-bis(benzyloxy)-2-methoxy-3,4-dihydro-2Hpyran-6-yl)methanol 52:

To the solution of 51 (0.58 g, 1.63 mmol) in methanol (15 mL) at 0 °C was added NaBH₄ (0.09 g, 2.29 mmol) and stirred at room temperature. After completion of reaction (TLC control, 30 min.), 5 mL of acetone was added to neutralize excess NaBH₄.

- 5 The solvent was then concentrated to dryness to give the residue that was dissolved in ethyl acetate (15 mL) and was washed with 2. water and brine. The organic layer was dried over Na₂SO₄ and evaporated under reduced pressure to obtain clear oil. Crude product was purified by column chromatography to yield
- 10 compound 52 (0.54 g, 94%) as a white gum. $[\alpha]_D^{28} = +21.5$ (c 1.5, CHCl₃); R_f 0.5 (1:1, EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (12.5/37.5, v/v); IR (Neat): 3428, 2920, 2366, 1682, 1454, 1094, 745, 699 cm⁻¹. ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3)$: δ 7.38- 7.21 (m, 10H), 4.99 (d, 1H, J = 2.9),
- 15 4.82 (d, 1H, J = 2.2), 4.75 (d, 1H, J = 1.5), 4.59 (s, 2H), 4.17-4.15 (m, 1H), 3.99 (s, 2H), 3.76- 3.73 (m, 1H), 3.48 (s, 3H), 2.12 (s, 1H); MS (ESI): m/z 379 (M⁺+Na). Anal. Calcd for C₂₁H₂₄O₅: C, 70.77; H, 6.79; Found: C, 70.82; H, 6.85.

(2S,3R,4R)-3,4-bis(benzyloxy)-2-methoxy-6-(4-

20 methoxybenzyl)hexahydrofuro[3,4-c]pyrano[2,3-d]isoxazol-7(9H)-one 53:

As described for 19, compound 53 was prepared from compound 52 (0.35 g, 0.98 mmol), 11 (0.41 g, 1.97 mmol), PyBroP (0.92 g, 1.97 mmol), DIPEA (0.68 mL, 3.95 mmol) and DMAP (0.13 g, 25 1.08 mmol). Crude product was purified by column

- chromatography to yield compound 53 (0.07 g, 62%) as a white solid. R_f 0.4 (4:1, EtOAc:Hexane). Eluent for column chromatography: EtOAc/Hexane (32/18, v/v); IR (Neat): 3010, 2930, 1754, 1678, 1603, 1510, 1452, 1256, 1031, 756 cm⁻¹. ¹H
- 30 NMR (300 MHz, CDCl₃): 8 8.23- 8.18 (m, 2H), 7.32-7.31 (m, 10H), 6.92- 6.88 (m, 2H), 5.08 (d, 1H, J = 4.4), 4.81 (d, 1H, J =3.6), 4.73 (d, 2H, J = 2.6), 4.69 (s, 2H), 4.60-4.59 (m, 1H), 4.35 (d, 1H, J = 8.8), 4.20- 4.15 (m, 1H), 3.81 (m, 3H), 3.76 (m, 2H),3.41 (s, 3H). ¹³C (75MHz, CDCl₃): δ 165.3, 161.5, 160.9, 159.0,
- 35 145.9, 138.1, 137.9, 136.9, 130.8, 129.7, 129.1, 128.4, 128.3, 128.2, 128.0, 127.8, 127.7, 127.6, 122.8, 114.2, 114.0, 113.8, 101.8, 99.4, 77.6, 76.9, 76.4, 75.8, 73.0, 72.9, 71.4, 67.3, 64.4, 56.6, 55.3, 55.2, 41.5; MS (ESI): *m/z* 570 (M⁺+Na). Anal. Calcd for C₃₁H₃₃NO₈: C, 67.99; H, 6.07; N, 2.56; Found: C, 67.91; H, 40 6.12; N, 2.62.

Acknowledgment.

The authors P.S. cordially thank CSIR for providing fellowships Financial support from BSC 0120 is 45 (NET-SRFs). acknowledged.

Notes and references

CDRI communication no xx

^a Medicinal and Process Chemistry Division, CSIR-Central 50 Drug Research Institute, B.S. 10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India. Tel: 91-522-2612411-18, Ext. 4661, 4662; Fax: 91-522-2623405

E-mail: gautam.panda@gmail.com; gautam_panda@cdri.res.in

- 55 † Electronic Supplementary Information (ESI) available: [1H and 13C NMR spectra for all the new compounds]. See DOI: 10.1039/b000000x/
 - 1. D. T. Hung, J. Chen and S. L. Schreiber, Chem. Biol. 1996, 3, 287-293.
- 2. G. G. Borisy and E. W. Taylor, J. Cell Biol. 1967, 34, 525-533.
- 3. G. G. Borisy and E. W. Taylor, J. Cell Biol. 1967, 34, 535-548
- 4. M. L. Shelanski and E. W. Taylor, J. Cell Biol. 1967, 34, 549-554.
- 5. O. Tamura, T. Okabe, T. Yamaguchi, K. Gotanda, K. Noe and M. Sakamoto, Tetrahedron 1995, 51, 107-118; O. Tamura, T. Okabe, T. Yamaguchi, J. Kotani, K. Gotanda and M. Sakamoto Tetrahedron 1995, 51, 119-128.
- 6. R. Ornelio, C. Massimo, M. Federica, M. Maria Carla and C. Giancarlo, Catalysis Letters, 2013, 143(2), 169-175.
- 7. R. J. Ferrier, J. Chem. Soc., Perkin Trans. 1 1979, 1455-
- 1458: R. J. Ferrier and O. A. Zubkov, Org. React. 2003, 62. doi:10.1002/0471264180.
- 8. J. Stefan, T. Joachim, Synthesis, 2006, 13, 2117-2120.
- 9. R. Huisgen, Angew. Chem. Int. Ed., 1963, 2 (10), 565-598.
- 10 K. V. Gothelf and K. A. Jørgensen, Chem. Rev. 1998, 98, 863-909; J. Marco-Contelles, E. de Opazo, Tetrahedron Letters. 1999, 40(23), 4445-4448; J. Marco-Contelles, Angew. Chem. 2004, 116, 2248-2250; J. P. Shilvock, K. Y. Hsia, R. J. Nash, J. D. Lloyd, A. L. Winters, N. Asano and G.W.J. Fleet, Tetrahedron Asymmetry, 1998, 9 (23), 4157-4164.
- 11. M. Saquib, I. Husain, B. Kumar and A. K. Shaw, Chem. Eur. J. 2009, 15, 6041-6049.
- 12. S. T. Derek, A. F. Michael, D. S. Matthew, S. L. Schreiber, J. Am. Chem. Soc. 1998, 120, 8565-8566.
- 13. D. Keirs, K. Overton, Heterocycles 1989, 28, 841-848.
- 14. A. V. Prosyanic, D. V. Fedoseenko and V. I. Markov, Zh. Org. Kim. 1985, 21, 1637 (Chem. Abstr. 1986, 105, 42309z).
- 15. R. Abdul, Canadian Journal of Chemistry, 1990, 68(7), 1122-7
- 16. S. Riku, K. Liisa T., European Journal of Organic Chemistry, 2013, 22, 4971-4978
- 17. J. Τ. Vazquez, W. Κ. Τ. Wiesler and Nakanishi, Carbohydrate Research, 1988, 176(2), 175-94.
- 18. L. V. Dunkerton, K. T. Brady, F. Mohamed and B. P. McKillican, Journal of Carbohydrate Chemistry, 1988, 7(1), 49-65.
- 19. A. M. Jordan, H. M. I. Osborn, P. M. Stafford, G. Tzortzis R. A. Rastall, Journal Carbohydrate and of Chemistry, 2003, 22(7 & 8), 705-717.
- 20. V. Serafin, B. Manuel, G. Ana M. and P. Pilar, Journal of Organic Chemistry, 1992, 57(16), 4546-4550.
- 21. B. Bernet and A. Vasella, Helv. Chim. Acta. 1979, 62, 1990; B. Bernet and A. Vasella, Helv. Chim. Acta 1979, 62, 2400; B. Bernet and A. Vasella, Helv. Chim. Acta. 1979, 62, 2411; B. S. Garegg, J. Chem. Soc., Perkin Trans. 1 1980, 2866.
- 22. V. Kumar, N. G. Ramesh, Tetrahedron 2006, 62, 1877-1885.

- 23 P. Q. Huang, X. Zheng and X. M. Deng *Tetrahedron Letters* 2001, 42, 9039–9041.
- 24. P. Ghosal, A. K. Shaw, *Journal of Organic Chemistry*, 2012, **77**(17), 7627-7632.
- 25. B. T. Reichstein, *Helvetica Chimica Acta*, 1946, **29**, 508-512.
- 26. B. Nils and K. Ove, Carbohydrate Research, 1977, 57, 65-71.
- 27. K. Joseph and R. D'Souza, Journal of Carbohydrates, Nucleosides, Nucleotides, 1980, 7(3), 141-157.
- 28. W. J. Hennen, H. M. Sweers, Yi Fong Wang, C. H. Wong,
- Journal of Organic Chemistry, 1988, 53(21), 4939-4945.
- 29. E. I. Balmond, D. M. Coe, M. C. Galan,; E. M. McGarrigle, *Angew Chem Int Ed*, 2012, **51**(36), 9152-9155.
- 30. M. Martine, L. Frederic, G. Jerome, N. Shinpei, K. Atsushi and B. Yves, *Bioorganic & Medicinal Chemistry*, 2013, **21**(16), 4803-4812.
- 31. M. Kyosuke, T. Manami and H. Masahiko, *Synthesis*, 2013, **45**(11), 1519-1523.
- 32. C. Giovanni, P. Francesco, B. Carlo and G. Cesare and N. Francesco, *Bioorganic & Medicinal Chemistry*, 2006, **14**(10), 3349-3367.
- 33. J. E. N. Shin, M. Asafu, M. Jean and A. S. Perlin, *Carbohydrate Research*, 1980, **84**(2), 328-335.
- 34. G. K. Rawal, S. Rani, A. Kumar and Y. D. Vankar, *Tetrahedron Letters*, 2006, 47(51), 9117-9120.
- 35. C. Vogel, P. Gries and *Journal of Carbohydrate Chemistry*, 1994, **13**(1), 37-46.
- 36. R. M. Giuliano and J. H. Buzby, *Journal of Carbohydrate Chemistry*, 1987, b(4), 541-552.

Linearization of carbohydrate derived polycyclic frameworks

Priyanka Singh,^a Gautam Panda*^a



We report an easy access to carbohydrate derived diverse tricyclic skeletons which could be beneficial for exploring polyfunctionalized chiral alicycles.